190 results on '"Bowcock, Stella"'
Search Results
2. Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination
3. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
4. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
5. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
6. Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination.
7. P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma
8. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
9. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
10. Patient-reported symptoms and diagnostic journey in Multiple Myeloma.
11. High numbers of COVID-19 patients transit through non-COVID wards, and associated healthcare workers have high infection rates: An observational cross-sectional study
12. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
13. Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
14. Cryptococcosis in late stage multiple myeloma: consider it
15. Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
16. Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials
17. Chemotherapy for cancer patients who present late
18. Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
19. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
20. Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study
21. Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience
22. Time to redefine Myeloma
23. Use of patient diaries in conjunction with standard reporting methods: duplication of data or a valuable resource?
24. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
25. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
26. Very poor performance status elderly patients with aggressive B cell lymphomas can benefit from intensive chemotherapy
27. Survival trends in elderly myeloma patients
28. Levofloxacin prophylaxis in patients with myeloma – Authors' reply
29. Ultra low dose thalidomide in myeloma revisited
30. Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
31. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
32. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
33. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma.
34. Ultra low dose thalidomide in elderly patients with myeloma
35. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders
36. Hemostatic studies in patients with infective endocarditis: a report on nine consecutive cases with evidence of coagulopathy
37. Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment
38. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
39. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
40. The combination of an inclusive novel agent treatment strategy, pre‐emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients
41. Levofloxacin Prophylaxis in Newly Diagnosed Myeloma Patients
42. Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018
43. 149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
44. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
45. Survival trends in elderly myeloma patients.
46. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection
47. Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
48. Medicine Among Nilotics In The Sud
49. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study
50. Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.